Purchase Order 75N92023P00308

Award Date 8/1/23
Potential Completion Date 7/31/24
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Baltimore, MD 21218, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded a $2.5 million delivery order contract to The Johns Hopkins University. The contract is for program management services to support the agency's efforts in high throughput genotyping and DNA sequencing for studying the genetic contributions to human health and disease. Work will be performed in Baltimore, Maryland over a one year base period ending in May 2021. A subcontract...
The National Institutes of Health's National Heart, Lung and Blood Institute awarded an $872,280 firm fixed price delivery order contract to The Johns Hopkins University. Under the contract, Johns Hopkins will provide genotyping global screening array services to the Brennan laboratory in support of the agency's cancer research programs. Performance will take place in Baltimore, Maryland over a three year period concluding in September 2022. The contract was awarded utilizing an unspecified...
The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded a $1.2 million firm fixed price delivery order to The Johns Hopkins University. This delivery order is being awarded against an unspecified government-wide acquisition contract vehicle and provides for the H3 AFRICA CONSORTIUM ARRAY FOR NCI (ADEBAMOWO) program. Work will be performed in Baltimore, Maryland over a three year period ending in September 2020. The prime...
This $116,480 firm fixed-price delivery order was awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to The Johns Hopkins University. The order supports "High Throughput Genotyping for Studying the Genetic Contributions to Human Disease" and does not include a set-aside designation. The Johns Hopkins University, a private research university, has extensive experience providing biomedical research, public health...
The National Heart Lung and Blood Institute (NHLBI), part of the U.S. Department of Health and Human Services, awarded a $2,253,160 firm-fixed-price delivery order contract to The Johns Hopkins University, a private research university. The contract, which does not have a set-aside designation, is for other functions related to high-throughput genotyping and DNA sequencing to study the genetic contribution to various conditions. The contract has a performance period through September 30, 2013....
This is a Firm Fixed Price delivery order contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to The Johns Hopkins University. The contract, valued at $143,766.00, is for high-throughput genotyping and DNA sequencing services to study the genetic contributions to human health and disease. This work supports the NHLBI's mission to promote the prevention and treatment of heart, lung, blood, and sleep disorders. The...
The Johns Hopkins University was awarded a $2,575,260 firm fixed price delivery order against an unspecified government-wide acquisition contract to provide custom targeted sequencing services to the National Institutes of Health's National Heart, Lung and Blood Institute. Specifically, the prime contractor will sequence approximately 250 genes from one-half formalin-fixed paraffin-embedded tumor samples and one-half matched normal samples to support the NIH's Fiscal Year 2017 Cancer research...
The National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. Department of Health and Human Services, awarded The Johns Hopkins University a $4,999,960 firm fixed-price delivery order contract to provide an Infinium Custom Single Nucleotide Polymorphism (SNP) panel with 600,000 bead types for the National Cancer Institute's Advancing Molecular Subtyping for Early-Stage Lung Cancer Study in Fiscal Year 2013. The contract has no set-aside designation and was competitively...
This is a firm fixed-price delivery order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to The Johns Hopkins University. The $10,270.00 contract supports high-throughput genotyping research to study the genetic contributions to human disease, as part of the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) program. The contract has a completion date of February 17, 2012 and was awarded on...
This is a firm fixed price delivery order contract awarded to The Johns Hopkins University by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), for "HUMANLINKAGE FOR NIMH (ESCAMILLA) FY 2011 CAN 8469682". The contract, which does not have a set-aside designation, has a ceiling value of $416,130.00 and a period of performance ending on February 17, 2012. The contract supports high throughput genotyping research to study the...

The National Institutes of Health, National Heart Lung and Blood Institute awarded a firm fixed price purchase order valued at twelve thousand dollars to The Johns Hopkins University. Under this contract, the prime contractor will support the Fitzhugh Joseph Lab, Cardiovascular and Myeloproliferative Disorders Branch, Leukemia Section Myeloproliferative Neoplasms Program by conducting research to identify genetic risk factors for myeloid malignancy development after curative therapies for sickle cell disease. The work will involve clonal hematopoiesis analysis in patients undergoing curative sickle cell disease treatments in order to determine cancer risks following such interventions. The period of performance is one year starting August 1, 2023 through July 31, 2024. No subcontractors or set aside designations were indicated.

Generated 12/16/23, 11:43 PM